Nimodipine Recommendations and Diagnostic Strategies for Subarachnoid Hemorrhage

Evidence‑Based Indications for Nimodipine in Aneurysmal SAH

The American Heart Association/American Stroke Association gives a Class I, Level A recommendation for nimodipine (60 mg every 4 hours for 21 days) in patients with aneurysmal subarachnoid hemorrhage to prevent delayed cerebral ischemia and improve functional outcomes. 1
Nimodipine and endovascular aneurysm repair (coiling) are the only two interventions that have demonstrated efficacy for subarachnoid hemorrhage in adequately powered, well‑controlled clinical trials. 1

CT angiography or digital subtraction angiography should be performed in all patients with subarachnoid hemorrhage to exclude an underlying aneurysm, especially when the hemorrhage pattern is atypical for trauma or the trauma history is uncertain. 1
Small aneurysms (< 3 mm) may be missed on initial imaging; repeat angiographic studies performed days to weeks later detect an additional 10 % of previously occult aneurysms. 1

The American Heart Association/American Stroke Association strongly recommends nimodipine for aneurysmal SAH, with early initiation of enteral nimodipine (60 mg every 4 hours for 21 days) beneficial in preventing delayed cerebral ischemia and improving functional outcomes 2, 3
The efficacy of nimodipine in aSAH has been confirmed in a meta-analysis of 16 trials involving 3,361 patients, demonstrating its effectiveness in this patient population 3

Management of traumatic SAH should focus on control of intracranial pressure, maintenance of cerebral perfusion pressure, prevention of secondary brain injury, and treatment of associated traumatic brain injuries 4